Global IgG4-Related Disease Market is Expected to Grow at 3.9% CAGR in the Forecast Period of 2021 to 2028

The Global IgG4-Related Disease Market is growing due to the surging volume of IgG4-related disease patients driving the market's growth. Increasing healthcare expenditure and rising collaborations among players are also propelling the growth of the global IgG4-related disease market. However, the high cost of treatment may hamper the growth of the market.

Global IgG4-Related Disease Market Scenario

According to Data Bridge Market Research, the global IgG4-related disease market in the Asia-Pacific region has the largest market share in the global IgG4-related disease market. Market leaders are Pfizer Inc. which accounts for an estimated market share of 10.21%. The company has gained outstanding sales through providing IgG4-related disease products.

For instance,

  • In November, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the business division of the company with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market

IgG4-Related Disease Market Trends Impacting the Market

Now the question is which other regions Pfizer Inc., Amgen Inc., Genentech, Inc. are targeting? Data Bridge Market Research has estimated a large growth in the North America IgG4-related disease market and the market leaders targeting U.S., Canada, and Mexico to be their next revenue pockets for 2021.

The global IgG4-related disease market is becoming more competitive with Pfizer Inc., Amgen Inc., Genentech, Inc., as they are the top dominating companies in the market with a maximum number of products. Data Bridge Market Research new reports highlight the major growth factors and opportunities in the global IgG4-related disease market.   

For more analysis on the global IgG4-related disease market, request a briefing with our analysts

Global IgG4-Related Disease Market Development

  • In September 2019, Genentech, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved Rituxan (rituximab). In combination with glucocorticoids, for treating granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients two years of age and older. GPA and MPA are rare, potentially life-threatening diseases affecting small- and medium-sized blood vessels. This will help the company to expand its business and make the product profile strong

Scope of the Global IgG4-Related Disease Market

The global IgG4-related disease market is segmented on the basis of countries into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. These regions are further segmented into major countries such as the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Austria, Sweden, Belgium, Estonia, and the Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of the Middle East and Africa.

The global IgG4-related disease market is categorized into five segments based on disease type, type, route of administration, end-user, and distribution channel.

  • On the basis of disease type, the global IgG4-related disease market is segmented into type 1 (IgG4-related) autoimmune pancreatitis (AIP), retroperitoneal fibrosis, IgG4-related tubulointerstitial nephritis (TIN), IgG4-related sclerosing cholangitis IgG4-related dacryoadenitis and sialadenitis, IgG4-related pachymeningitis, IgG4-related thyroid disease, serum IgG4 concentration, and others. On the basis of type, the global IgG4-related disease market is segmented into diagnostic and treatment. On the basis of route of administration, the global IgG4-related disease market is segmented into oral, parenteral, and others. On the basis of end-user, the global IgG4-related disease market is segmented into hospitals, specialty clinics, others. On the basis of distribution channel, the global IgG4-related disease market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.

To know more about the report:

Key Pointers Covered in Global IgG4-Related Disease Market Industry Trends and Forecast to 2028

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries

Key Market Competitors Covered in the Report

The key market players for the global IgG4-related disease market are listed below:

  • Zydus Cadila
  • Hikma Pharmaceuticals PLC
  • Lannett
  • Sun Pharmaceutical Industries Ltd
  • Baxter
  • Viatris Inc.
  • Amgen Inc.
  • Sandoz International GmbH (a subsidiary of Novartis AG)
  • Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA)
  • Pfizer Inc.
  • Cipla Inc.
  • Celltrion Healthcare Co., Ltd.
  • Antares Pharma,
  • Amneal Pharmaceuticals LLC.
  • Accord-UK Ltd.
  • Genentech, Inc.
  • Ingenus Pharmaceuticals  
  • ANI Pharmaceuticals, Inc.

Above are the key players covered in the report. To know about more an exhaustive list of Global IgG4-related disease market companies, contact us

Research Methodology: Global IgG4-Related Disease Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or can drop down your inquiry.

The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market timeline analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis, and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Clinicians, Healthcare Professionals, Researchers, Academicians.
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers, among others.

Related Reports

Browse in Healthcare Category Related Reports@